Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications
Abstract Additional chromosome abnormalities (ACAs) occur in less than 10% of cases at diagnosis of Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML). In some cases, on the basis of the persistence of the ACAs in Ph-negative cells after response to imatinib, a secondary origin...
Gespeichert in:
| Veröffentlicht in: | Cancer genetics and cytogenetics 2010-06, Vol.199 (2), p.76-80 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 80 |
|---|---|
| container_issue | 2 |
| container_start_page | 76 |
| container_title | Cancer genetics and cytogenetics |
| container_volume | 199 |
| creator | Zaccaria, Alfonso Testoni, Nicoletta Valenti, Anna Maria Luatti, Simona Tonelli, Michela Marzocchi, Giulia Cipriani, Raffaella Baldazzi, Carmen Giannini, Barbara Stacchini, Monica Gamberini, Carla Castagnetti, Fausto Rosti, Gianantonio Azzena, Annalisa Cavazzini, Francesco Cianciulli, Anna Maria Dalsass, Alessia Donti, Emilio Giugliano, Emilia Gozzetti, Alessandro Grimoldi, Maria Grazia Ronconi, Sonia Santoro, Alessandra Spedicato, Francesco Zanatta, Lucia Baccarani, Michele |
| description | Abstract Additional chromosome abnormalities (ACAs) occur in less than 10% of cases at diagnosis of Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML). In some cases, on the basis of the persistence of the ACAs in Ph-negative cells after response to imatinib, a secondary origin of the Ph chromosome has been demonstrated. In this study, the possible prognostic value of this phenomenon was evaluated. Thirty-six Ph-positive CML patients were included in the study. In six patients, ACAs persisted after the disappearance of the Ph. A complete cytogenetic response (CCR) was obtained in five of these six patients, and five of six also had a high Sokal score. In all the other cases, ACAs disappeared together (in cases of response to therapy with imatinib) or persisted with the Ph (in cases of no response to imatinib). In the former cases, the primary origin of the Ph was demonstrated. CCR was obtained in 22 cases (17 with low to intermediate Sokal scores), while no response was observed in 8 patients (5 with a high Sokal score). Sokal score seems to maintain its prognostic value for patients in whom the Ph occurs as a primary event, but not in those in whom it occurs as a secondary one. |
| doi_str_mv | 10.1016/j.cancergencyto.2010.02.003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733119086</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165460810000579</els_id><sourcerecordid>733119086</sourcerecordid><originalsourceid>FETCH-LOGICAL-c437t-78a2b0c75a8f9587f37b9057d24c66195b587fd3c44f6279868a9a04aa574373</originalsourceid><addsrcrecordid>eNqNUk1v1DAQtRAV3Rb-ArLEgVMWO19OQEJCqxaQKhWJ3q2JPWm8deJgO0j7Y_ivON2CaE-cbM-892bGbwh5w9mWM16_228VTAr9LU7qEN02ZynD8i1jxTOy4Y0osrKs6udkk9BVVtasOSVnIewZYyJv6xfkNGel4BVrN-TXbvBudMGNSKGbnB_BmmgwUNA6XdwElkZH44D022AsaLTzYICqf3jxPq0N3E4umEBdf5-ejKLjAa1LnbolUIvLHY4G3tMZ4rBGMSYITJrO3q3c9WnG2RoFa-nwkpz0YAO-ejjPyc3lxc3uS3Z1_fnr7tNVpspCxEw0kHdMiQqavq0a0Reia1kldF6quuZt1a1BXaiy7OtctE3dQAusBKhEEijOydujbGrjx4IhytEEhdbChKlxKYqC85Y1dUJ-OCKVdyF47OXszQj-IDmTqztyLx-5I1d3JMtlciexXz_UWboR9V_uHzsS4OIIwDTsT4NeBmWSEGrjUUWpnfnPQh-f6Chrkh1g7_CAYe8Wn3wNksuQCPL7uijrnvC0Iunf2uI3LhfBqA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733119086</pqid></control><display><type>article</type><title>Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Zaccaria, Alfonso ; Testoni, Nicoletta ; Valenti, Anna Maria ; Luatti, Simona ; Tonelli, Michela ; Marzocchi, Giulia ; Cipriani, Raffaella ; Baldazzi, Carmen ; Giannini, Barbara ; Stacchini, Monica ; Gamberini, Carla ; Castagnetti, Fausto ; Rosti, Gianantonio ; Azzena, Annalisa ; Cavazzini, Francesco ; Cianciulli, Anna Maria ; Dalsass, Alessia ; Donti, Emilio ; Giugliano, Emilia ; Gozzetti, Alessandro ; Grimoldi, Maria Grazia ; Ronconi, Sonia ; Santoro, Alessandra ; Spedicato, Francesco ; Zanatta, Lucia ; Baccarani, Michele</creator><creatorcontrib>Zaccaria, Alfonso ; Testoni, Nicoletta ; Valenti, Anna Maria ; Luatti, Simona ; Tonelli, Michela ; Marzocchi, Giulia ; Cipriani, Raffaella ; Baldazzi, Carmen ; Giannini, Barbara ; Stacchini, Monica ; Gamberini, Carla ; Castagnetti, Fausto ; Rosti, Gianantonio ; Azzena, Annalisa ; Cavazzini, Francesco ; Cianciulli, Anna Maria ; Dalsass, Alessia ; Donti, Emilio ; Giugliano, Emilia ; Gozzetti, Alessandro ; Grimoldi, Maria Grazia ; Ronconi, Sonia ; Santoro, Alessandra ; Spedicato, Francesco ; Zanatta, Lucia ; Baccarani, Michele ; GIMEMA Working Party on CML</creatorcontrib><description>Abstract Additional chromosome abnormalities (ACAs) occur in less than 10% of cases at diagnosis of Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML). In some cases, on the basis of the persistence of the ACAs in Ph-negative cells after response to imatinib, a secondary origin of the Ph chromosome has been demonstrated. In this study, the possible prognostic value of this phenomenon was evaluated. Thirty-six Ph-positive CML patients were included in the study. In six patients, ACAs persisted after the disappearance of the Ph. A complete cytogenetic response (CCR) was obtained in five of these six patients, and five of six also had a high Sokal score. In all the other cases, ACAs disappeared together (in cases of response to therapy with imatinib) or persisted with the Ph (in cases of no response to imatinib). In the former cases, the primary origin of the Ph was demonstrated. CCR was obtained in 22 cases (17 with low to intermediate Sokal scores), while no response was observed in 8 patients (5 with a high Sokal score). Sokal score seems to maintain its prognostic value for patients in whom the Ph occurs as a primary event, but not in those in whom it occurs as a secondary one.</description><identifier>ISSN: 0165-4608</identifier><identifier>EISSN: 1873-4456</identifier><identifier>DOI: 10.1016/j.cancergencyto.2010.02.003</identifier><identifier>PMID: 20471509</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents - therapeutic use ; Benzamides ; Chromosome Aberrations ; Female ; Hematology, Oncology and Palliative Medicine ; Humans ; Imatinib Mesylate ; Karyotyping ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics ; Male ; Medical Education ; Middle Aged ; Philadelphia Chromosome ; Piperazines - therapeutic use ; Protein-Tyrosine Kinases - antagonists & inhibitors ; Pyrimidines - therapeutic use ; Remission Induction ; Treatment Outcome</subject><ispartof>Cancer genetics and cytogenetics, 2010-06, Vol.199 (2), p.76-80</ispartof><rights>Elsevier Inc.</rights><rights>2010 Elsevier Inc.</rights><rights>Copyright 2010 Elsevier Inc. All rights reserved.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c437t-78a2b0c75a8f9587f37b9057d24c66195b587fd3c44f6279868a9a04aa574373</citedby><cites>FETCH-LOGICAL-c437t-78a2b0c75a8f9587f37b9057d24c66195b587fd3c44f6279868a9a04aa574373</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.cancergencyto.2010.02.003$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20471509$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zaccaria, Alfonso</creatorcontrib><creatorcontrib>Testoni, Nicoletta</creatorcontrib><creatorcontrib>Valenti, Anna Maria</creatorcontrib><creatorcontrib>Luatti, Simona</creatorcontrib><creatorcontrib>Tonelli, Michela</creatorcontrib><creatorcontrib>Marzocchi, Giulia</creatorcontrib><creatorcontrib>Cipriani, Raffaella</creatorcontrib><creatorcontrib>Baldazzi, Carmen</creatorcontrib><creatorcontrib>Giannini, Barbara</creatorcontrib><creatorcontrib>Stacchini, Monica</creatorcontrib><creatorcontrib>Gamberini, Carla</creatorcontrib><creatorcontrib>Castagnetti, Fausto</creatorcontrib><creatorcontrib>Rosti, Gianantonio</creatorcontrib><creatorcontrib>Azzena, Annalisa</creatorcontrib><creatorcontrib>Cavazzini, Francesco</creatorcontrib><creatorcontrib>Cianciulli, Anna Maria</creatorcontrib><creatorcontrib>Dalsass, Alessia</creatorcontrib><creatorcontrib>Donti, Emilio</creatorcontrib><creatorcontrib>Giugliano, Emilia</creatorcontrib><creatorcontrib>Gozzetti, Alessandro</creatorcontrib><creatorcontrib>Grimoldi, Maria Grazia</creatorcontrib><creatorcontrib>Ronconi, Sonia</creatorcontrib><creatorcontrib>Santoro, Alessandra</creatorcontrib><creatorcontrib>Spedicato, Francesco</creatorcontrib><creatorcontrib>Zanatta, Lucia</creatorcontrib><creatorcontrib>Baccarani, Michele</creatorcontrib><creatorcontrib>GIMEMA Working Party on CML</creatorcontrib><title>Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications</title><title>Cancer genetics and cytogenetics</title><addtitle>Cancer Genet Cytogenet</addtitle><description>Abstract Additional chromosome abnormalities (ACAs) occur in less than 10% of cases at diagnosis of Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML). In some cases, on the basis of the persistence of the ACAs in Ph-negative cells after response to imatinib, a secondary origin of the Ph chromosome has been demonstrated. In this study, the possible prognostic value of this phenomenon was evaluated. Thirty-six Ph-positive CML patients were included in the study. In six patients, ACAs persisted after the disappearance of the Ph. A complete cytogenetic response (CCR) was obtained in five of these six patients, and five of six also had a high Sokal score. In all the other cases, ACAs disappeared together (in cases of response to therapy with imatinib) or persisted with the Ph (in cases of no response to imatinib). In the former cases, the primary origin of the Ph was demonstrated. CCR was obtained in 22 cases (17 with low to intermediate Sokal scores), while no response was observed in 8 patients (5 with a high Sokal score). Sokal score seems to maintain its prognostic value for patients in whom the Ph occurs as a primary event, but not in those in whom it occurs as a secondary one.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Benzamides</subject><subject>Chromosome Aberrations</subject><subject>Female</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Imatinib Mesylate</subject><subject>Karyotyping</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics</subject><subject>Male</subject><subject>Medical Education</subject><subject>Middle Aged</subject><subject>Philadelphia Chromosome</subject><subject>Piperazines - therapeutic use</subject><subject>Protein-Tyrosine Kinases - antagonists & inhibitors</subject><subject>Pyrimidines - therapeutic use</subject><subject>Remission Induction</subject><subject>Treatment Outcome</subject><issn>0165-4608</issn><issn>1873-4456</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUk1v1DAQtRAV3Rb-ArLEgVMWO19OQEJCqxaQKhWJ3q2JPWm8deJgO0j7Y_ivON2CaE-cbM-892bGbwh5w9mWM16_228VTAr9LU7qEN02ZynD8i1jxTOy4Y0osrKs6udkk9BVVtasOSVnIewZYyJv6xfkNGel4BVrN-TXbvBudMGNSKGbnB_BmmgwUNA6XdwElkZH44D022AsaLTzYICqf3jxPq0N3E4umEBdf5-ejKLjAa1LnbolUIvLHY4G3tMZ4rBGMSYITJrO3q3c9WnG2RoFa-nwkpz0YAO-ejjPyc3lxc3uS3Z1_fnr7tNVpspCxEw0kHdMiQqavq0a0Reia1kldF6quuZt1a1BXaiy7OtctE3dQAusBKhEEijOydujbGrjx4IhytEEhdbChKlxKYqC85Y1dUJ-OCKVdyF47OXszQj-IDmTqztyLx-5I1d3JMtlciexXz_UWboR9V_uHzsS4OIIwDTsT4NeBmWSEGrjUUWpnfnPQh-f6Chrkh1g7_CAYe8Wn3wNksuQCPL7uijrnvC0Iunf2uI3LhfBqA</recordid><startdate>20100601</startdate><enddate>20100601</enddate><creator>Zaccaria, Alfonso</creator><creator>Testoni, Nicoletta</creator><creator>Valenti, Anna Maria</creator><creator>Luatti, Simona</creator><creator>Tonelli, Michela</creator><creator>Marzocchi, Giulia</creator><creator>Cipriani, Raffaella</creator><creator>Baldazzi, Carmen</creator><creator>Giannini, Barbara</creator><creator>Stacchini, Monica</creator><creator>Gamberini, Carla</creator><creator>Castagnetti, Fausto</creator><creator>Rosti, Gianantonio</creator><creator>Azzena, Annalisa</creator><creator>Cavazzini, Francesco</creator><creator>Cianciulli, Anna Maria</creator><creator>Dalsass, Alessia</creator><creator>Donti, Emilio</creator><creator>Giugliano, Emilia</creator><creator>Gozzetti, Alessandro</creator><creator>Grimoldi, Maria Grazia</creator><creator>Ronconi, Sonia</creator><creator>Santoro, Alessandra</creator><creator>Spedicato, Francesco</creator><creator>Zanatta, Lucia</creator><creator>Baccarani, Michele</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100601</creationdate><title>Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications</title><author>Zaccaria, Alfonso ; Testoni, Nicoletta ; Valenti, Anna Maria ; Luatti, Simona ; Tonelli, Michela ; Marzocchi, Giulia ; Cipriani, Raffaella ; Baldazzi, Carmen ; Giannini, Barbara ; Stacchini, Monica ; Gamberini, Carla ; Castagnetti, Fausto ; Rosti, Gianantonio ; Azzena, Annalisa ; Cavazzini, Francesco ; Cianciulli, Anna Maria ; Dalsass, Alessia ; Donti, Emilio ; Giugliano, Emilia ; Gozzetti, Alessandro ; Grimoldi, Maria Grazia ; Ronconi, Sonia ; Santoro, Alessandra ; Spedicato, Francesco ; Zanatta, Lucia ; Baccarani, Michele</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c437t-78a2b0c75a8f9587f37b9057d24c66195b587fd3c44f6279868a9a04aa574373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Benzamides</topic><topic>Chromosome Aberrations</topic><topic>Female</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Imatinib Mesylate</topic><topic>Karyotyping</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics</topic><topic>Male</topic><topic>Medical Education</topic><topic>Middle Aged</topic><topic>Philadelphia Chromosome</topic><topic>Piperazines - therapeutic use</topic><topic>Protein-Tyrosine Kinases - antagonists & inhibitors</topic><topic>Pyrimidines - therapeutic use</topic><topic>Remission Induction</topic><topic>Treatment Outcome</topic><toplevel>online_resources</toplevel><creatorcontrib>Zaccaria, Alfonso</creatorcontrib><creatorcontrib>Testoni, Nicoletta</creatorcontrib><creatorcontrib>Valenti, Anna Maria</creatorcontrib><creatorcontrib>Luatti, Simona</creatorcontrib><creatorcontrib>Tonelli, Michela</creatorcontrib><creatorcontrib>Marzocchi, Giulia</creatorcontrib><creatorcontrib>Cipriani, Raffaella</creatorcontrib><creatorcontrib>Baldazzi, Carmen</creatorcontrib><creatorcontrib>Giannini, Barbara</creatorcontrib><creatorcontrib>Stacchini, Monica</creatorcontrib><creatorcontrib>Gamberini, Carla</creatorcontrib><creatorcontrib>Castagnetti, Fausto</creatorcontrib><creatorcontrib>Rosti, Gianantonio</creatorcontrib><creatorcontrib>Azzena, Annalisa</creatorcontrib><creatorcontrib>Cavazzini, Francesco</creatorcontrib><creatorcontrib>Cianciulli, Anna Maria</creatorcontrib><creatorcontrib>Dalsass, Alessia</creatorcontrib><creatorcontrib>Donti, Emilio</creatorcontrib><creatorcontrib>Giugliano, Emilia</creatorcontrib><creatorcontrib>Gozzetti, Alessandro</creatorcontrib><creatorcontrib>Grimoldi, Maria Grazia</creatorcontrib><creatorcontrib>Ronconi, Sonia</creatorcontrib><creatorcontrib>Santoro, Alessandra</creatorcontrib><creatorcontrib>Spedicato, Francesco</creatorcontrib><creatorcontrib>Zanatta, Lucia</creatorcontrib><creatorcontrib>Baccarani, Michele</creatorcontrib><creatorcontrib>GIMEMA Working Party on CML</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer genetics and cytogenetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zaccaria, Alfonso</au><au>Testoni, Nicoletta</au><au>Valenti, Anna Maria</au><au>Luatti, Simona</au><au>Tonelli, Michela</au><au>Marzocchi, Giulia</au><au>Cipriani, Raffaella</au><au>Baldazzi, Carmen</au><au>Giannini, Barbara</au><au>Stacchini, Monica</au><au>Gamberini, Carla</au><au>Castagnetti, Fausto</au><au>Rosti, Gianantonio</au><au>Azzena, Annalisa</au><au>Cavazzini, Francesco</au><au>Cianciulli, Anna Maria</au><au>Dalsass, Alessia</au><au>Donti, Emilio</au><au>Giugliano, Emilia</au><au>Gozzetti, Alessandro</au><au>Grimoldi, Maria Grazia</au><au>Ronconi, Sonia</au><au>Santoro, Alessandra</au><au>Spedicato, Francesco</au><au>Zanatta, Lucia</au><au>Baccarani, Michele</au><aucorp>GIMEMA Working Party on CML</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications</atitle><jtitle>Cancer genetics and cytogenetics</jtitle><addtitle>Cancer Genet Cytogenet</addtitle><date>2010-06-01</date><risdate>2010</risdate><volume>199</volume><issue>2</issue><spage>76</spage><epage>80</epage><pages>76-80</pages><issn>0165-4608</issn><eissn>1873-4456</eissn><abstract>Abstract Additional chromosome abnormalities (ACAs) occur in less than 10% of cases at diagnosis of Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML). In some cases, on the basis of the persistence of the ACAs in Ph-negative cells after response to imatinib, a secondary origin of the Ph chromosome has been demonstrated. In this study, the possible prognostic value of this phenomenon was evaluated. Thirty-six Ph-positive CML patients were included in the study. In six patients, ACAs persisted after the disappearance of the Ph. A complete cytogenetic response (CCR) was obtained in five of these six patients, and five of six also had a high Sokal score. In all the other cases, ACAs disappeared together (in cases of response to therapy with imatinib) or persisted with the Ph (in cases of no response to imatinib). In the former cases, the primary origin of the Ph was demonstrated. CCR was obtained in 22 cases (17 with low to intermediate Sokal scores), while no response was observed in 8 patients (5 with a high Sokal score). Sokal score seems to maintain its prognostic value for patients in whom the Ph occurs as a primary event, but not in those in whom it occurs as a secondary one.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>20471509</pmid><doi>10.1016/j.cancergencyto.2010.02.003</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0165-4608 |
| ispartof | Cancer genetics and cytogenetics, 2010-06, Vol.199 (2), p.76-80 |
| issn | 0165-4608 1873-4456 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733119086 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Adult Aged Aged, 80 and over Antineoplastic Agents - therapeutic use Benzamides Chromosome Aberrations Female Hematology, Oncology and Palliative Medicine Humans Imatinib Mesylate Karyotyping Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics Male Medical Education Middle Aged Philadelphia Chromosome Piperazines - therapeutic use Protein-Tyrosine Kinases - antagonists & inhibitors Pyrimidines - therapeutic use Remission Induction Treatment Outcome |
| title | Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T05%3A05%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chromosome%20abnormalities%20additional%20to%20the%20Philadelphia%20chromosome%20at%20the%20diagnosis%20of%20chronic%20myelogenous%20leukemia:%20pathogenetic%20and%20prognostic%20implications&rft.jtitle=Cancer%20genetics%20and%20cytogenetics&rft.au=Zaccaria,%20Alfonso&rft.aucorp=GIMEMA%20Working%20Party%20on%20CML&rft.date=2010-06-01&rft.volume=199&rft.issue=2&rft.spage=76&rft.epage=80&rft.pages=76-80&rft.issn=0165-4608&rft.eissn=1873-4456&rft_id=info:doi/10.1016/j.cancergencyto.2010.02.003&rft_dat=%3Cproquest_cross%3E733119086%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733119086&rft_id=info:pmid/20471509&rft_els_id=S0165460810000579&rfr_iscdi=true |